[ad_1]
So Paulo, 07 – A new candidate for the HIV preventive vaccine had an immune response – it was tolerated and caused a reaction in the body – in humans and in monkeys. In the case of animals, the immunizing potential also guarantees the blockage of the virus. More than 30 years after the identification of the HIV virus, scientists are still working on the development of a preventative vaccine that can help prevent the spread of HIV in the developing world, according to a new study published in the Lancet review. End the epidemic that infects about 2 million people each year. In this study, a group of scientists evaluated the prevalence of a number of vaccination regimens for HIV prevention in human volunteers from five countries. Meanwhile, another team tested the same vaccine in rhesus monkeys to find out if it would be able to protect animals from infection with the virus.
The results showed that the vaccine induces a robust immune response in humans and monkeys. In addition, monkeys became partially immune to HIV infection. "In animals, the vaccine provided about 67% protection against the virus," said study co-ordinator Dan Barouch of the Beth Israel Deaconess Medical Center (USA)
. previously limited to specific regions of the world. The new immunizer of a type known as mosaic vaccine, which contains different genetic sequences from several different strains of HIV. According to the researcher, this type of vaccination aims to provide sufficient protection against the different strains of HIV that prevail worldwide.
The trials included testing five different Ad26 / Env vaccine regimens to badess their safety and tolerability, as well as their ability to elicit immune responses in 393 healthy adult volunteers. Based on these data, the vaccine progressed to the next phase of the clinical trials, to determine whether it would be possible to determine if the vaccine was available in the United States, (19659002). Clinical trials involve the participation of 2,600 South African women who may be infected with HIV. "Our goal is that the results be ready between 2021 and 2022. This is only the fifth vaccine concept to test for efficacy in humans throughout the more than 35-year history of the disease. 39, the global epidemic of HIV, "said the scientist. Professor at Harvard Medical School (United States)
Barouch says, however, that good results must be interpreted with caution. "The challenges to developing an HIV vaccine are unprecedented and the ability to induce specific immune responses against this virus does not necessarily indicate that the vaccine protects humans from HIV infection," was -he says. Millions of people around the world are living with HIV / AIDS and about 1.8 million new cases are registered each year. "A safe and effective preventive vaccine is urgently needed to reduce the HIV pandemic."
Since the beginning of the epidemic, only four concepts of HIV vaccines have been tested in humans and only one has provided evidence of protection in an efficacy test – gp120, which has been tested in Thailand and reduces the rate of infection in humans by 31%. However, the effect was considered too low for the vaccine to be used.
The new study was also followed by scientists from the Ragon Institute – HIV Study Center established in 2009 in partnership between Harvard, the Mbadachusetts Institute of Technology (MIT) and Mbadachusetts General Hospital -, the US Military HIV Research Program, the National Institute of Allergy and Infectious Diseases, the International AIDS Vaccine Initiative, the Multiple HIV Test other partners. The information is from the newspaper
The State of São Paulo.
(Fbio de Castro)
Source link
